Prognostic Value of Complement System in NSCLC and its Association with PD-1 and PD-L1 Expression

被引：1

作者：

Ajona, D. ^{[1
]}

Pajares, M. J. ^{[2
]}

Freire, J. ^{[3
]}

Gomez-Roman, J. ^{[3
]}

Martinez-Terroba, E. ^{[4
]}

Ortiz-Espinosa, S. ^{[4
]}

Lledo, A. ^{[4
]}

Arenas-Lazaro, E. ^{[4
]}

Agorreta, J. ^{[4
]}

Lecanda, F. ^{[4
]}

Montuenga, L. ^{[4
]}

Pio, R. ^{[4
]}

机构：

[1] Cima Univ Navarra Idisna Ciberonc, Program Solid Tumors & Biomarkers, Pamplona, Spain

[2] Univ Navarra, Ctr Appl Med Res CIMA, Program Solid Tumors, Pamplona, Spain

[3] Univ Hosp Marques Valdecilla, Santander, Spain

[4] Cima, Pamplona, Spain

来源：

JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期

关键词：

PD-L1; Prognosis; Complement system;

D O I：

10.1016/j.jtho.2018.08.407

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MA11.06

引用

页码：S394 / S394

页数：1

共 50 条

[41] Prognostic value of PD-1 and PD-L1 expression in patients with metastatic clear cell renal cell carcinoma
Ueda, Kosuke
Suekane, Shigetaka
Kurose, Hirofumi
Chikui, Katsuaki
Nakiri, Makoto
Nishihara, Kiyoaki
Matsuo, Mitsunori
Kawahara, Akihiko
Yano, Hirohisa
Igawa, Tsukasa
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2018, 36 (11) : 499.e9 - 499.e16
[42] Expression of PD-1/PD-L1 in lung adenocarcinoma and its clinical significance
Jian Li
Yimin Chen
Oncology and Translational Medicine, 2021, 7 (01) : 15 - 19
[43] Efficacy of PD-1/PD-L1 Immune Checkpoint Inhibitors for Advanced NSCLC According to PD-L1 Expression: A Meta-Analysis
Ma, K.
Guo, Y.
Wang, Y.
Wang, X.
Xu, Y.
Sun, C.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S584 - S584
[44] Highly Activated PD-1/PD-L1 Pathway in Gastric Cancer with PD-L1 Expression
Saito, Hiroaki
Kono, Yusuke
Murakami, Yuki
Shishido, Yuji
Kuroda, Hirohiko
Matsunaga, Tomoyuki
Fukumoto, Yoji
Osaki, Tomohiro
Ashida, Keigo
Fujiwara, Yoshiyuki
ANTICANCER RESEARCH, 2018, 38 (01) : 107 - 112
[45] Study on the Expression Levels and Clinical Significance of PD-1 and PD-L1 in Plasma of NSCLC Patients
He, Jiabei
Pan, Yuanqing
Guo, Yang
Li, Baolan
Tang, Yu
JOURNAL OF IMMUNOTHERAPY, 2020, 43 (05) : 156 - 164
[46] Prognostic value of PD-1, PD-L1 and PD-L2 deserves attention in head and neck cancer
Jiang, Siqing
Li, Xin
Huang, Lihua
Xu, Zhensheng
Lin, Jinguan
FRONTIERS IN IMMUNOLOGY, 2022, 13
[47] PD-L1 expression as a predictor of postoperative recurrence and the association between the PD-L1 expression and EGFR mutations in NSCLC
Kojima, Kensuke
Sakamoto, Tetsuki
Kasai, Takahiko
Kagawa, Tomoko
Yoon, Hyungeun
Atagi, Shinji
SCIENTIFIC REPORTS, 2021, 11 (01)
[48] PD-L1 expression as a predictor of postoperative recurrence and the association between the PD-L1 expression and EGFR mutations in NSCLC
Kensuke Kojima
Tetsuki Sakamoto
Takahiko Kasai
Tomoko Kagawa
Hyungeun Yoon
Shinji Atagi
Scientific Reports, 11
[49] PD-1/PD-L1 inhibitors
Sunshine, Joel
Taube, Janis M.
CURRENT OPINION IN PHARMACOLOGY, 2015, 23 : 32 - 38
[50] PD-1/PD-L1 in disease
Kuol, Nyanbol
Stojanovska, Lily
Nurgali, Kulmira
Apostolopoulos, Vasso
IMMUNOTHERAPY, 2018, 10 (02) : 149 - 161

← 1 2 3 4 5 →